abs379.txt	objectives		to	model	the	cost-effectiveness	of	a	biomarker-based	approach	toselect	patients	for	neoadjuvant	chemotherapy	(nac)	before	radical	cystectomy	(rc)in	muscle-invasive	bladder	cancer	(mibc)	patients	and	methods		we	obtained	data	from	the	most	recent	clinical	studies	onpatients	with	locally	advanced	mibc	treated	by	rc		including	stage	distributions	overall	survival	(os)	estimates		associated	costs		and	utilisation/response	tonac		additionally		we	estimated	the	putative	efficacy	of	three	biomarkers	toselect	patients	for	nac		dna-repair	gene	panel	[ataxia	telangiectasia	mutated(atm)		retinoblastoma	1	(rb1)		and	fanconi	anaemia	complementation	group	c(fancc)]		excision	repair	cross-complementation	group	2	(ercc2)		and	ribonucleicacid	(rna)	subtypes		a	decision	analysis	model	was	developed	to	evaluate	thecost-effectiveness	of	biomarker-based	approaches	to	select	patients	with	mibc	fornac		comparison	of	cost-effectiveness	included	rc	alone		unselected	nac	plus	rc	and	nac	based	on	the	three	aforementioned	biomarkers	results		the	dna-repair	gene	panel-based	approach	to	nac	was	the	mostcost-effective	strategy	(mean	os	of	3	14	years		$31	482/life	year)		under	thisapproach		38%	would	undergo	nac		about	twice	the	number	of	patients	who	arecurrently	receiving	nac	for	mibc		such	an	approach	would	improve	mean	os	by	5	2	1	6		and	4	4	months	compared	to	rc	alone		a	hypothetical	scenario	where	allpatients	received	nac		and	compared	to	current	estimates	of	nac	utilisation	respectively	conclusions		a	biomarker-based	strategy	to	identify	patients	with	mibc	who	shouldundergo	nac	was	more	cost-effective	than	unselected	use	of	nac	or	rc	alone		asfurther	data	becomes	available		such	a	model	may	serve	as	a	basis	forincorporating	biomarkers	into	clinical	decision	making	
